The Swiss pharma company Novartis ranks in the top 10 of pharma companies, and boasts drugs ranging from Ritalin and Lamisil to clozapine, Diovan and Gilenya. It also owns the generic giant Sandoz. Unlike its competitor, GlaxoSmithKline, Novartis did not offer free flu vaccines during the H1N1 flu epidemic.

In March 2011, Novartis gained FDA approval for Gilenya, its multiple sclerosis drug. The nod came on the heels of a narrower EMA approval, which grants second-line treatment status. According to experts, the drug could be worth $3 billion in annual sales as the first oral MS drug on the market.

Novartis purchased the remaining portion of eye care company Alcon in a $12.9 billion deal at the end of 2010, marking the end of one of the biggest battles in biopharma. Although many analysts predicted heavy layoffs in 2010 from the company, only 1,400 jobs were cut in December 2010, with the disclaimer that more could be on the way as Novartis, like others in the industry, analyzes its efficiency.

Tag:

Novartis

Latest Headlines

Latest Headlines

Novartis beefs up its cancer immunotherapy pipeline with a biotech buyout

Novartis is gobbling up a startup biotech in the U.S. that could help provide an entry into the frenzied race for PD-1 targeting therapies, announcing this morning that it had struck a deal to buy CoStim Pharmaceuticals, a low-profile biotech based in Cambridge, MA, and listed as part of Atlas Venture's group of companies.

Novartis CEO Jimenez looking for new places to hatchet blockbuster R&D budget

Novartis may have a long way to go before it's done cutting its blockbuster R&D budget. With a major strategic review underway, Novartis CEO Joe Jimenez told analysts that its massive drug research operation still offers a fresh source of spending cuts--even after a number of moves aimed at concentrating more of its R&D operations in the company's main research hubs in the U.S., Europe and Asia.

Novartis aims for super-speed with strategic review, CEO tells analysts

Want the latest on Novartis' should-we-or-shouldn't-we asset review? Leerink Partners analysts met with CEO Joe Jimenez recently, so they can deliver that and more, including some hints at cost-cutting targets.

The most influential people in biopharma today

Any industry that's undergoing as much change as biopharma is always looking for leadership. Old marketing practices are being blown apart, R&D is being subjected to emergency surgery, drug...

Novartis is expanding a plant in Singapore

Novartis is expanding a plant in Singapore and the international engineering and construction firm PM Group is helping.

Buzz: Novartis mulls selling its vaccine unit as swap deal with Merck stalls

Last week Novartis' vaccine unit posted yet another operating loss, extending its streak in the red to four years. Yet despite its well-known, long-term problems, suitors are reportedly circling the unit, with the potential of Bexsero and Menveo likely to be a factor attracting potential buyers.

The top drug delivery partnerships of 2013

In the biotech and pharma industries, drug delivery is a crucial aspect of research and development. Finding new ways to deliver old drugs, ways to make a new drug more efficient or ways that make a...

Novartis vaccine unit is no wallflower: It has suitors flirting with a deal, too

A couple of weeks back, the Street was abuzz that Merck would hand over its consumer-health business for Novartis' animal-health and vaccines units.  Yesterday, word was that Merck has some consumer-goods giants shopping its consumer-health aisle.

Novartis slashing thousands more jobs in global reorganization, shifting many to India

Novartis' 500 Swiss job cuts announced earlier this month are just the tip of a global iceberg. The company plans to cut or shuffle up to 4,000 jobs in its pharma business, with many of the positions moving to a new operations center in Hyderabad, India, a Swiss newspaper reports.

Novartis: We cannot keep shipping Bexsero under investigational license

Novartis is trying to make its meningitis B vaccine Bexsero widely available in the U.S., instead of just supplying it on an ad hoc basis to tackle outbreaks.